

**ANSELL LIMITED ANNOUNCES THE CLOSING OF THE SALE
OF ITS SEXUAL WELLNESS BUSINESS**

4 September, 2017 – Ansell Limited (ASX:ANN), a global leader in protection solutions, today announces the closing of the previously announced sale of its Sexual Wellness (“SW”) business to Humanwell Healthcare (Group) Co., Ltd. and CITIC Capital China Partners III, L.P. (collectively, the “Buyer Consortium”) for US\$600M.

All pre-completion conditions and regulatory approvals have been satisfied globally and sale proceeds received, with the exception of some pre-completion conditions relating to Ansell’s Brazilian condom business, Blowtex. Ansell and the Buyer Consortium anticipated the need for additional time to conclude the sale of Blowtex and as agreed, US\$10M of the sale proceeds will remain in escrow until the Brazilian completion conditions are satisfied, which is expected to occur by end of September 2017.

As previously announced the net after-tax cash proceeds to Ansell are expected to be US\$529M and the Company also expects to realise a net profit after tax in the order of US\$365M subject to closing entries. This gain will be recorded in the F’18 accounts.

The sale represents the successful conclusion to the portfolio review announced in August 2016 with regards to the Sexual Wellness business and is now being followed up by the recently announced Sharper Focus Transformation program and US\$265M share buy-back.

J.K. Ansell Indian Joint Venture

Ansell today also announces it has reached agreement with Raymond Limited, its joint venture partner in J. K. Ansell Private Limited in India, to restructure the Indian joint venture such that:

- a) Raymond will take full ownership of the J. K. condom business including the Kama Sutra brand, while
- b) Ansell will have full ownership of the Indian medical business which sells medical gloves and hospital safety solutions in a separate legal entity.

The sale will result in a net payment to Ansell of approximately US\$1M. Closing is expected to be in the second half of the F’18 year.

ENDS

=====

For further information:

Investors & Analysts

Australia	David Graham, I.R.	Tel: +61(0) 3 9270 7215 / +61 (0) 401 140 749	david.graham@ansell.com
Belgium	Neil Salmon, CFO	Tel: +32 (0) 2 528 75 59	neil.salmon@ansell.com

Media

Australia	Andrew Stokes, FTI Consulting	Tel: + 61 (0) 2 8298 6114/ +61 (0) 416 967 038	andrew.stokes@fticonsulting.com
US	Tom Paoella, Communications	Tel: +1 732 345 2167	tom.paoella@ansell.com

ASX Announcement



About Ansell

Ansell is a world leader in providing superior health and safety protection solutions that enhance human well-being. The world's need for better protection never stops, so Ansell is constantly researching, developing and investing to manufacture and distribute cutting edge product innovation and technology, marketed under well-known brands that customers trust.

Operating in two main business segments, Industrial and Healthcare, Ansell is the market leader that continues to grow, employing 13,000 people worldwide. With operations in North America, Latin America/Caribbean, EMEA and Asia Pacific, customers in more than 100 countries around the world trust Ansell and its protection solutions.

Information on Ansell and its products can be found at www.ansell.com. #AnsellProtects

HyFlex[®] GAMMEX[®] SKYN[®] AlphaTec[®] MICR@FLEX[®]

Ansell, [®] and [™] are trademarks owned by Ansell Limited or one of its affiliates. US Patented and US and non-US Patents Pending:

www.ansell.com/patentmarking © 2017 Ansell Limited. All Rights Reserved